Mandate

Vinge advises SBB on its offer for Hemfosa

November 15, 2019 Capital Markets and Public M&A

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) has announced a recommended public offer to the shareholders of Hemfosa Fastigheter AB (publ) (“Hemfosa”) to tender all their shares in Hemfosa to SBB.

The total offer consideration consists of a combination of cash and SBB shares. At announcement, the total offer value for all Hemfosa shares is approximately SEK 23.5 billion. SBB is a major Nordic social infrastructure property company with a property portfolio with a market value of SEK 30.8 billion as of 30 September 2019. SBB’s Class B and Class D common shares are listed in Nasdaq Stockholm, Large Cap.

SBB has retained Vinge as legal advisor. The Vinge team mainly consist of Jesper Schönbeck, Erik Sjöman, Rikard Lindahl, Malte Hedlund, Boris Kotur and Clara Sohlberg, and Albert Wållgren, Ludvig Wettergren and Axel Jansson (on finance matters), Trine Osen Bergqvist and Johan Wahlbom (on competition matters) and Maria Schultzberg and Victor Ericsson (on tax matters).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026